Five-year data support the use of pembrolizumab plus pemetrexed-platinum chemotherapy as standard care for previously untreated, metastatic, EGFR/ALK-wild-type NSCLC, according to researchers.
All articles by Leah Lawrence
Quality metrics for cancer screening tests vary across cancer types, but most metrics are not supported by evidence, a study suggests.
Older patients with advanced NSCLC do not derive the same survival benefit from immune checkpoint inhibitors as younger patients.
Postmenopausal cancer survivors have greater declines in physical function than cancer-free control individuals, a new study suggests.
Cancer patients have an increased risk of suicide when compared with the general population in the United States, a study suggests.
A deep learning model called Sybil can predict a person’s risk of lung cancer using a single low-dose CT scan, a study suggests.
Tumor mutational burden can predict outcomes of chemoradiation plus durvalumab in patients with stage III non-small cell lung cancer, a study suggests.
Researchers have identified noncardiac biomarkers that may predict myocarditis associated with immune checkpoint inhibitor treatment.
Researchers have found a lack of consistency in trial designs and reporting of results for phase 3 oncology trials with biomarker validation.
The legalization of medical marijuana has been linked to reductions in opioid dispensing and pain-related hospital visits in patients with cancer.
Frequent CT surveillance after surgery for stage I non-small cell lung cancer does not improve survival outcomes, a study suggests.
The incidence of stage I lung cancer increased between 2010 and 2017, according to data from more than 1.4 million US patients with lung cancer.
Serious adverse events were reported less frequently among patients enrolled in cancer trials during the first 2 years of the COVID-19 pandemic than among patients enrolled prior to the pandemic.
Critical variables for 3 of the highest-volume cancers were not measured under the Oncology Care Model, according to researchers.
An estimated 3% to 6% of patients with limited-stage small-cell lung cancer develop grade 3-5 pneumonitis after concurrent chemoradiation.
Guideline-adherent care was associated with better survival, regardless of disease stage.
From 2010 to 2019, the percentage of oncology practices with medically integrated dispensing more than doubled.
The pooled incidence of chemoradiation-induced grade 3-5 pneumonitis was 3.62% in randomized trials, 5.98% in observational studies, and 7.85% in observational studies of platinum doublet chemotherapy.
TACTI-002, enrolled 114 patients with untreated locally advanced or metastatic non-small cell lung cancer, unselected for PD-L1 expression.
Results showed a median overall survival of 25.0 months for chemo-immunotherapy vs 20.9 months for immunotherapy alone.
The researchers noted that responses were deep, with 75% of responders achieving a greater than 50% tumor reduction.
The overall response rate was 33%, with 1% of patients having complete responses and 32% having partial responses.
The percentage of patients with stage I disease increased from 23.5% in 2010 to 29.1% in 2017.
Younger patients with cancer are “a high-risk population for poor outcomes from COVID-19,” according to researchers.
The lack of guideline-concordant care for early-stage non-small cell lung cancer may affect the interpretation of adjuvant trial results, according to researchers.
Researchers sought to determine whether use of tumor match and adaptive RT improved incidence of adverse events and survival outcomes in patients with NSCLC.
Factors associated with greater odds of nonconcordant radiotherapy included receipt of major procedures or chemotherapy and survival more than 30 days after the treatment planning appointment.
Radiotherapy did not improve response rates or survival outcomes.
Compared with patients who had a medium platelet count, patients with a very high platelet count had more than double the risk of a solid tumor diagnosis.
The greatest reductions in enrollment were seen in cancer control and prevention trials.
Latest News Your top articles for TuesdayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses